Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.86 UNCHANGED

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues ↗

August 12, 2024

FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...

Via Benzinga

New Study Reveals How Classical Music Could Revolutionize Depression Care

August 12, 2024

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...

Via PressReach

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday? ↗

August 07, 2024

Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP patients. Adzynma is the first enzyme replacement therapy in the EU for this...

Via Benzinga

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

August 07, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024 ↗

July 31, 2024

Takeda Pharmaceutical just reported results for the first quarter of 2024.

Via InvestorPlace

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

July 31, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

3 Biotech Stocks to Buy on the Dip: July 2024 ↗

July 29, 2024

Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.

Via InvestorPlace

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation ↗

July 24, 2024

Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK...

Via Benzinga

Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst ↗

July 09, 2024

Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to...

Via Benzinga

Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma ↗

July 06, 2024

Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was...

Via Talk Markets

Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report ↗

July 02, 2024

Blackstone Inc. is reportedly finalizing a deal to sell Alinamin Pharmaceutical to MBK Partners for $2.17 billion. Blackstone acquired Alinamin from Takeda in 2020.

Via Benzinga

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 ↗

June 28, 2024

Protagonist Therapeutics will join the SmallCap 600 on Wednesday.

Via Investor's Business Daily

Topics Stocks

Takeda Announces New Assignments of Directors

June 26, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

June 24, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

June 22, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

June 21, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

June 21, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

June 18, 2024

Via Benzinga

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

June 18, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 17, 2024

Via Benzinga

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? ↗

June 17, 2024

Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.

Via Benzinga

Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies ↗

June 17, 2024

Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes

Via Benzinga

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

June 17, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare ↗

June 15, 2024

Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...

Via Talk Markets

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

June 14, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts

June 11, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

7 F-Rated Stocks to Avoid at All Costs in June ↗

June 06, 2024

The stock market is doing well this year, so it would be a tragedy to own F-rated stocks. Here are some key stocks to avoid in June.

Via InvestorPlace

Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report ↗

June 03, 2024

Blackstone reportedly considers sale of Japanese consumer healthcare firm Alinamin Pharmaceutical (previously owned by Takeda) for $1.9B, attracting interest from other firms.

Via Benzinga

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

June 03, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

June 01, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.